Significance of Ectopic Lymph Node-Like Structures in Neuroendocrine Tumors of the Small Bowel Abstract #1181

Introduction: The formation of extranodal tertiary lymphoid follicles and lymphoid cell aggregates has been described in nonmalignant conditions including autoimmune diseases and chronic inflammation as well as in cancer. Tumor-induced lymph node-like structures (LLS) participate in the host’s antitumor immune response by driving intratumoral immune cell priming
Aim(s): To evaluate the prognostic relevance and biologic significance of an adaptive immune reaction to small bowel NETs
Materials and methods: Host immune response was evaluated by IHC in 60 well differentiated small bowel NETs. A miRNA microarray analysis was performed to identify a molecular signature of LLS presence
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Dr. Mauro Cives

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1561 PD1 and PDL1 Expression in Midgut Neuroendocrine Tumors
Introduction: PD1/PDL1 inhibitors have shown promising results in different carcinomas, and correlation between PDL1 expression and response to immunotherapy has been reported. No studies thus far have investigated the expression of PD1 or PDL1 in midgut NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Mauro Cives
#2199 Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET)
Introduction: Immunotherapy is being explored in many tumour types with encouraging results, but
its role in the management of NET is yet to be defined.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Clare Vesely
#1273 Tissue Prognostic Markers in Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours (pNETs) are a rare, heterogeneous class of neoplasms, with a rising incidence. Prognosis is variable with 5-year survival as low as 16% in inoperable tumours.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr Jonathan Dunbar
Authors: Dunbar J, Tod J, Horne J, Armstrong T, ...
#2047 IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83
Introduction: SSAs are used in the treatment of G1/G2 Neuroendocrine Neoplasms (NEN) in order to control symptoms and induce tumor shrinkage with an excellent tolerability profile. The role of immune response is crucial in defining the clinical response to treatment through the active stimulation of effector cells (T and NK cells) but also through the inhibition of tumor-induced immune suppression. The immune regulatory cells CD4-CD25-expressing Tregs and myeloid cellsMDSC can contribute to disease progression through various mechanisms.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Salvatore Tafuto
#1179 A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results
Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives
Authors: Cives M, Strosberg J, Campos T, Weber T, ...